Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.02.2016 | short review

Treatment of elderly patients with diffuse large B-cell lymphoma

verfasst von: Thomas Nösslinger, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

With the implementation of rituximab, tremendous progress has been achieved in the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, the majority of patients with DLBCL are over the age of 65 years and the management of these patients is often suboptimal. Standard chemo-immunotherapy with curative approach should be appropriate for all elderly patients who can tolerate it. Therefore, a careful evaluation of each patient is mandatory prior to treatment allocation. R- CHOP regimen (rituximab, cyclophosphamide doxorubicin, vincristine, prednisolone) remains the standard of care, but special attention has to be paid to rigorous supportive care. Patients not fit enough for R-CHOP are candidates for dose-reduced therapy or other palliative strategies.
Vorheriger Artikel Treatment of elderly and very old patients with AML
Nächster Artikel Treatment of elderly patients with melanoma
Literatur
1.
Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;31:128–36.CrossRefPubMed
2.
3.
Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology, but not the immune-histochemical GCB/non-GCB classfier, predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial. Blood. 2010;116(23):4916–25.CrossRefPubMed
4.
Thunberg U, Enblad G, Berglund M. Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup. Haematologica. 2012;97(2):e3; author reply e4.CrossRefPubMedPubMedCentral
5.
The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive Non-Hodgkin’s Lymphoma. N Engl J Med. 1993;329:987–94.CrossRef
6.
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.CrossRefPubMed
7.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.CrossRefPubMed
8.
Savage K, Zeynalova S, Kansara R, et al. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Blood (ASH Annual Meeting Abstracts), 124: 2014, (abstr 394).
9.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
10.
Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622–6.CrossRefPubMed
11.
Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246–54.CrossRefPubMed
12.
Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25(14):1824–31.CrossRefPubMed
13.
Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale. Psychiatry Res. 1992;41(3):237–48.CrossRefPubMed
14.
Wilson WH, Jung SH, Porcu P, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758–65.CrossRefPubMedPubMedCentral
15.
Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–90.CrossRefPubMedPubMedCentral
16.
Fields A, Linch D. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol. 2012;157:159–70.CrossRefPubMed
17.
Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–41.CrossRefPubMed
18.
Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116(24):5103–10.CrossRefPubMed
19.
Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258–63.CrossRefPubMed
20.
Lamy T, Damaj G, Gyan E, et al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02–03 trial from the Lysa/Goelams group. Blood (ASH Annual Meeting Abstracts), 124: 2014, (abstr 393).
21.
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.CrossRefPubMed
22.
Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16.CrossRefPubMed
23.
Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–26.CrossRefPubMed
24.
Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14(6):525–33.CrossRefPubMed
25.
Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32(11):1112–8.CrossRefPubMed
26.
Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460–8.CrossRefPubMed
27.
Fridrik M, Petzer A, Keil F, et al. Non-pegylated liposomal encapsulated doxorubicin reduces cardiotoxicity in 1st line treatment of diffuse large B-cell lymphoma (DLBCL). Final Results of a Randomized Trial Blood (ASH Annual Meeting Abstracts), 118: 2011, (abstr 2676).
28.
Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22(8):1839–44.CrossRefPubMed
29.
Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–20.CrossRefPubMed
30.
El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363–8.CrossRefPubMed
31.
Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012;13(7):696–706. (Erratum in: Lancet Oncol. 2012 Jul;13(7):e285).CrossRefPubMed
Metadaten
Titel
Treatment of elderly patients with diffuse large B-cell lymphoma
verfasst von
Thomas Nösslinger, MD
Publikationsdatum
01.02.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0248-6

Weitere Artikel der Ausgabe 1/2016

Never too old to treat cancer?

  • editorial

Adjuvant medical treatment for breast cancer in elderly and old women

  • Open Access
  • short review

Treatment of elderly patients with advanced urological cancer

  • review

New approaches in graft versus host disease (GvHD) management

  • short review

Erratum to: A review on biomolecular basis of the role of psychological stress in the development and progression of cancer

  • Erratum

Intensive care for cancer patients

  • Open Access
  • review